TrialClinical and translational science2026

A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of Adiponectin Agonist (PEG)-BHD1028 in People With Insulin Resistance.

Pablo Lapuerta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.